Role of LCAT in atherosclerosis

Journal of Atherosclerosis and Thrombosis

Volumn 23, Issue 2, 2016, Pages 119-127

  Ossoli, Alice ^a   Simonelli, Sara ^a   Vitali, Cecilia ^a   Franceschini, Guido ^a   Calabresi, Laura ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Atherosclerosis; Genetic LCAT deficiency; HDL; Lecithin:cholesterol acyltransferase

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN A1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ARTERIAL STIFFNESS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME SYNTHESIS; HUMAN; LIPID METABOLISM; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TRANSESTERIFICATION; ANIMAL; GENETICS; METABOLISM; RISK FACTOR;

ANIMALS; ATHEROSCLEROSIS; HUMANS; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RISK FACTORS;

EID: 84957111134     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.32854     Document Type: Review

References (57)

1. Glomset JA. The plasma lecithin: cholesterol acyltransferase reaction. J Lipid Res, 1968; 9: 155-162
2. Nakamura Y, Kotite L, Gan Y, Spencer TA, Fielding CJ, Fielding PE. Molecular mechanism of reverse cholesterol transport: reaction of pre-beta-migrating high-density lipoprotein with plasma lecithin/cholesterol acyltransferase. Biochemistry, 2004; 43: 14811-14820
3. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta, 2000; 1529: 245-256
4. Warden CH, Langner CA, Gordon JI, Taylor BA, McLean JW, Lusis AJ. Tissue-specific expression, developmental regulation, and chromosomal mapping of the lecithin: cholesterol acyltransferase gene. J Biol Chem, 1989; 264: 21573-21581
5. Glukhova A, Hinkovska-Galcheva V, Kelly R, Abe A, Shayman JA, Tesmer JJ. Structure and function of lysosomal phospholipase A2 and lecithin: cholesterol acyltransferase. Nat Commun, 2015; 6: 6250
6. Piper DE, Romanow WG, Gunawardane RN, Fordstrom P, Masterman S, Pan O, Thibault ST, Zhang R, Meininger D, Schwarz M, Wang Z, King C, Zhou M, Walker NP. The high resolution crystal structure of human LCAT. J Lipid Res, 2015;
7. Albers JJ, Bergelin RO, Adolphson JL, Wahl PW. Population- based reference values for lecithin: cholesterol acyltransferase (LCAT). Atherosclerosis, 1982; 43: 369-379
8. Murakami T, Michelagnoli S, Longhi R, Gianfranceschi G, Pazzucconi F, Calabresi L, Sirtori CR, Franceschini G. Triglycerides are major determinants of cholesterol esterification/ transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol, 1995; 15: 1819-1828
9. Calabresi L, Pisciotta L, Costantin A, Frigerio I, Eberini I, Alessandrini P, Arca M, Bon GB, Boscutti G, Busnach G, Frasca G, Gesualdo L, Gigante M, Lupattelli G, Montali A, Pizzolitto S, Rabbone I, Rolleri M, Ruotolo G, Sampietro T, Sessa A, Vaudo G, Cantafora A, Veglia F, Calandra S, Bertolini S, Franceschini G. The molecular basis of lecithin: cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol, 2005; 25: 1972-1978
10. Dobiasova M, Frohlich J, Sedova M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res, 2011; 52: 566-571
11. Zhao Y, Thorngate FE, Weisgraber KH, Williams DL, Parks JS. Apolipoprotein E Is the Major Physiological Activator of Lecithin-Cholesterol Acyltransferase (LCAT) on Apolipoprotein B Lipoproteins. Biochemistry, 2005; 44: 1013-1025
12. Vitali C, Wellington CL, Calabresi L. HDL and cholesterol handling in the brain. Cardiovasc Res, 2014; 103: 405-413
13. Jonas A. Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. Biochim Biophys Acta, 1991; 1084: 205-220
14. Rye KABarter PJ. Formation and metabolism of prebetamigrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol, 2004; 24: 421-428
15. Chetiveaux M, Lalanne F, Lambert G, Zair Y, Ouguerram K, Krempf M. Kinetics of prebeta HDL and alphaHDL in type II diabetic patients. Eur J Clin Invest, 2006; 36: 29-34
16. Franceschini G, Maderna P, Sirtori CR. Reverse cholesterol transport: physiology and pharmacology. Atherosclerosis, 1991; 88: 99-107
17. Czarnecka HYokoyama S. Regulation of cellular cholesterol efflux by lecithin: cholesterol acyltransferase reaction through nonspecific lipid exchange. J Biol Chem, 1996; 271: 2023-2028
18. Tanigawa H, Billheimer JT, Tohyama JI, Fuki IV, Ng DS, Rothblat GH, Rader DJ. Lecithin: cholesterol acyltransferase expression has minimal effects on macrophage reverse cholesterol transport in vivo. Circulation, 2009; 120: 160-169
19. Schwartz CC, Vlahcevic ZR, Berman M, Meadows JG, Nisman RM, Swell L. Central role of high density lipoprotein in plasma free cholesterol metabolism. J Clin Invest, 1982; 70: 105-116
20. Schwartz CC, VandenBroek JM, Cooper PS. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J Lipid Res, 2004; 45: 1594-1607
21. Calabresi L, Simonelli S, Gomaraschi M, Franceschini G. Genetic lecithin: cholesterol acyltransferase deficiency and cardiovascular disease. Atherosclerosis, 2012; 222: 299- 306
22. Santamarina-Fojo S, Hoeg JM, Assmann G, Brewer HBRJr. Lecithin cholesterol acyltransferase deficiency and fish eye disease, In C. R. Scriver, A. L. Beaudet, W. S. Sly, and D. Valle (eds.), The Metabolic and Molecular Bases of Inherited Diseases. McGraw-Hill, New York, 2001; 2817-2833
23. Asztalos BF, Schaefer EJ, Horvath KV, Yamashita S, Miller M, Franceschini G, Calabresi L. Role of LCAT in HDL remodeling: investigation of LCAT deficiency states. J Lipid Res, 2007; 48: 592-599
24. Forte TM, Norum KR, Glomset JA, Nichols AV. Plasma lipoproteins in familial lecithin: cholesterol acyltransferase deficiency. Structure of low and high density lipoproteins as revealed by electron microscopy. J Clin Invest, 1971; 50: 1141-1148
25. Vaisman BL, Klein HG, Rouis M, Berard AM, Kindt MR, Talley GD, Meyn SM, Hoyt RF, Jr., Marcovina SM, Albers JJ. Overexpression of human lecithin cholesterol acyltransferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem, 1995; 270: 12269-12275
26. Mehlum A, Muri M, Hagve TA, Solberg LA, Prydz H. Mice overexpressing human lecithin: cholesterol acyltransferase are not protected against diet-induced atherosclerosis. APMIS, 1997; 105: 861-868
27. Berard AM, Foger B, Remaley A, Shamburek R, Vaisman BL, Talley G, Paigen B, Hoyt RF, Jr., Marcovina S, Brewer HBJr, Santamarina-Fojo S. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase. Nat Med, 1997; 3: 744-749
28. Thacker SG, Rousset X, Esmail S, Zarzour A, Jin X, Collins HL, Sampson M, Stonik J, Demosky S, Malide DA, Freeman L, Vaisman BL, Kruth HS, Adelman SJ, Remaley AT. Increased plasma cholesterol esterification by LCAT reduces diet-induced atherosclerosis in SR-BI knockout mice. J Lipid Res, 2015; 56: 1282-1295
29. Foger B, Chase M, Amar MJ, Vaisman BL, Shamburek RD, Paigen B, Fruchart-Najib J, Paiz JA, Koch CA, Hoyt RF, Brewer HBJr, Santamarina-Fojo S. Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice. J Biol Chem, 1999; 274: 36912-36920
30. Sakai N, Vaisman BL, Koch CA, Hoyt RF, Jr., Meyn SM, Talley GD, Paiz JA, Brewer HBJr, Santamarina-Fojo S. Targeted disruption of the mouse lecithin: cholesterol acyltransferase (LCAT) gene. Generation of a new animal model for human LCAT deficiency. J Biol Chem, 1997; 272: 7506-7510
31. Ng DS, Francone OL, Forte TM, Zhang J, Haghpassand M, Rubin EM. Disruption of the murine lecithin: cholesterol acyltransferase gene causes impairment of adrenal lipid delivery and up-regulation of scavenger receptor class B type I. J Biol Chem, 1997; 272: 15777-15781
32. Furbee JW, Jr., Sawyer JK, Parks JS. Lecithin: cholesterol acyltransferase deficiency increases atherosclerosis in the low density lipoprotein receptor and apolipoprotein E knockout mice. J Biol Chem, 2002; 277: 3511-3519
33. Lambert G, Sakai N, Vaisman BL, Neufeld EB, Marteyn B, Chan CC, Paigen B, Lupia E, Thomas A, Striker LJ, Blanchette-Mackie J, Csako G, Brady JN, Costello R, Striker GE, Remaley AT, Brewer HBJr, Santamarina-Fojo S. Analysis of glomerulosclerosis and atherosclerosis in lecithin: cholesterol acyltransferase-deficient mice. J Biol Chem, 2001; 276: 15090-15098
34. Hoeg JM, Vaisman BL, Demosky SJ, Jr., Meyn SM, Talley GD, Hoyt RF, Jr., Feldman S, Berard AM, Sakai N, Wood D, Brousseau ME, Marcovina SM, Brewer HBJr, Santamarina-Fojo S, Marcovina S. Lecithin: cholesterol acyltransferase overexpression generates hyperalpha-lipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem, 1996; 271: 4396-4402
35. Hoeg JM, Santamarina-Fojo S, Berard AM, Cornhill JF, Herderick EE, Feldman SH, Haudenschild CC, Vaisman BL, Hoyt RF, Jr., Demosky SJ, Jr., Kauffman RD, Hazel CM, Marcovina SM, Brewer HBJr. Overexpression of lecithin: cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci U S A, 1996; 93: 11448-11453
36. Amar MJ, Shamburek RD, Vaisman B, Knapper CL, Foger B, Hoyt RF, Jr., Santamarina-Fojo S, Brewer HB, Jr., Remaley AT. Adenoviral expression of human lecithincholesterol acyltransferase in nonhuman primates leads to an antiatherogenic lipoprotein phenotype by increasing high-density lipoprotein and lowering low-density lipoprotein. Metabolism, 2009; 58: 568-575
37. Holleboom AG, Kuivenhoven JA, Vergeer M, Hovingh GK, van Miert JN, Wareham NJ, Kastelein JJ, Khaw KT, Boekholdt SM. Plasma levels of lecithin: cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective casecontrol analysis nested in the EPIC-Norfolk population study. J Lipid Res, 2010; 51: 416-421
38. Haase CL, Tybjaerg-Hansen A, Ali QA, Schou J, Nordestgaard BG, Frikke-Schmidt R. LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individ- uals. J Clin Endocrinol Metab, 2012; 97: E248-E256
39. Hovig T, Gjone E. Familial plasma lecithin: cholesterol acyltransferase (LCAT) deficiency. Ultrastructural aspects of a new syndrome with particular reference to lesions in the kidneys and the spleen. Acta Pathol Microbiol Scand A, 1973; 81: 681-697
40. Wells IC, Peitzmeier G, Vincent JK. Lecithin: cholesterol acyltransferase and lysolecithin in coronary atherosclerosis. Exp Mol Pathol, 1986; 45: 303-310
41. Solajic-Bozicevic N, Stavljenic-Rukavina A, Sesto M. Lecithin- cholesterol acryltransferase activity in patients with coronary artery disease examined by coronary angiography. Clin Investig, 1994; 72: 951-956
42. Dullaart RP, Perton F, Sluiter WJ, De VR, Van TA. Plasma lecithin: cholesterol acyltransferase activity is elevated in metabolic syndrome and is an independent marker of increased carotid artery intima media thickness. J Clin Endocrinol Metab, 2008; 93: 4860-4866
43. Dullaart RP, Perton F, van der Klauw MM, Hillege HL, Sluiter WJ. High plasma lecithin: cholesterol acyltransferase activity does not predict low incidence of cardiovascular events: possible attenuation of cardioprotection associated with high HDL cholesterol. Atherosclerosis, 2010; 208: 537-542
44. Calabresi L, Baldassarre D, Simonelli S, Gomaraschi M, Amato M, Castelnuovo S, Frigerio B, Ravasi A, Sansaro D, Kauhanen J, Rauramaa R, de FU, Hamsten A, Smit AJ, Mannarino E, Humphries SE, Giral P, Veglia F, Sirtori CR, Franceschini G, Tremoli E. Plasma lecithin: cholesterol acyltransferase and carotid intima-media thickness in European individuals at high cardiovascular risk. J Lipid Res, 2011; 52: 1569-1574
45. Tani S, Takahashi A, Nagao K, Hirayama A. Association of lecithin-cholesterol acyltransferase activity measured as a serum cholesterol esterification rate and low-density lipoprotein heterogeneity with cardiovascular risk: a crosssectional study. Heart Vessels, 2015;
46. Sethi AA, Sampson M, Warnick R, Muniz N, Vaisman B, Nordestgaard BG, Tybjaerg-Hansen A, Remaley AT. High pre-beta1 HDL concentrations and low lecithin: cholesterol acyltransferase activities are strong positive risk markers for ischemic heart disease and independent of HDL-cholesterol. Clin Chem, 2010; 56: 1128-1137
47. Dullaart RP, Tietge UJ, Kwakernaak AJ, Dikkeschei BD, Perton F, Tio RA. Alterations in plasma lecithin: cholesterol acyltransferase and myeloperoxidase in acute myocardial infarction: Implications for cardiac outcome. Atherosclerosis, 2014; 234: 185-192
48. Ayyobi AF, McGladdery SH, Chan S, John Mancini GB, Hill JS, Frohlich JJ. Lecithin: cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis, 2004; 177: 361-366
49. Calabresi L, Baldassarre D, Castelnuovo S, Conca P, Boc chi L, Candini C, Frigerio B, Amato M, Sirtori CR, Alessandrini P, Arca M, Boscutti G, Cattin L, Gesualdo L, Sampietro T, Vaudo G, Veglia F, Calandra S, Franceschini G. Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation, 2009; 120: 628-635
50. Hovingh GK, Hutten BA, Holleboom AG, Petersen W, Rol P, Stalenhoef A, Zwinderman AH, de GE, Kastelein JJ, Kuivenhoven JA. Compromised LCAT function is associated with increased atherosclerosis. Circulation, 2005; 112: 879-884
51. Duivenvoorden R, Holleboom AG, van den BB, Nederveen AJ, de GE, Hutten BA, Schimmel AW, Hovingh GK, Kastelein JJ, Kuivenhoven JA, Stroes ES. Carriers of lecithin: cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging. J Am Coll Cardiol, 2011; 58: 2481-2487
52. van den Bogaard B, Holleboom AG, Duivenvoorden R, Hutten BA, Kastelein JJ, Hovingh GK, Kuivenhoven JA, Stroes ES, van den Born BJ. Patients with low HDL-cholesterol caused by mutations in LCAT have increased arterial stiffness. Atherosclerosis, 2012; 225: 481-485
53. Calabresi L, Simonelli S, Conca P, Busnach G, Cabibbe M, Gesualdo L, Gigante M, Penco S, Veglia F, Franceschini G. Acquired lecithin: cholesterol acyltransferase deficiency as a major factor in lowering plasma HDL levels in chronic kidney disease. J Intern Med, 2015; 277: 552-561
54. Favari E, Lee M, Calabresi L, Franceschini G, Zimetti F, Bernini F, Kovanen PT. Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding Cassette Transporter A1- but not Scavenger Receptor Class B Type I-mediated lipid efflux to high density lipoprotein. J Biol Chem, 2004; 279: 9930-9936
55. Calabresi L, Favari E, Moleri E, Adorni MP, Pedrelli M, Costa S, Jessup W, Gelissen IC, Kovanen PT, Bernini F, Franceschini G. Functional LCAT is not required for macrophage cholesterol efflux to human serum. Atherosclerosis, 2009; 204: 141-146
56. Khera AV, Cuchel M, De LL-M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med, 2011; 364: 127-135
57. Saleheen D, Scott R, Javad S, Zhao W, Rodrigues A, Picataggi A, Lukmanova D, Mucksavage ML, Luben R, Billheimer J, Kastelein JJ, Boekholdt SM, Khaw KT, Wareham N, Rader DJ. Association of HDL cholesterol efflux capacity with incident coronary heart disease events: a prospective case-control study. Lancet Diabetes Endocrinol, 2015; 3: 507-513